A carregar...
Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the FcγRIIB Receptor
The development of neutralizing antibodies (inhibitors) against factor VIII (FVIII) is a major complication of hemophilia A treatment. The sole clinical therapy to restore FVIII tolerance in patients with inhibitors remains immune tolerance induction (ITI) which is expensive, difficult to administer...
Na minha lista:
| Publicado no: | Front Immunol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7025534/ https://ncbi.nlm.nih.gov/pubmed/32117285 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.00138 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|